Quick Takeaways
- Baselake Partners, LP filed SCHEDULE 13G/A for Neuphoria Therapeutics Inc. Common Stock, $0.00001 par value per share (NEUP).
- Disclosed ownership: 4.1%.
- Date of event: 31 Dec 2025.
Baselake Partners, LP - 31 Dec 2025 SCHEDULE 13G/A Report for Neuphoria Therapeutics Inc. Common Stock, $0.00001 par value per share (NEUP)
- Filing Manager
- Baselake Partners, LP
- Reporting Manager
- Baselake Partners, LP
- Symbol
- NEUP
- Shares outstanding
- 5,420,049 shares
- Disclosed Ownership
- 222,222 shares
- Ownership
- 4.1%
- Form type
- SCHEDULE 13G/A
- Filing time
- 06 Feb 2026, 16:29:13 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 31 Oct 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Baselake Partners, LP disclosed 4.1% ownership in Neuphoria Therapeutics Inc. Common Stock, $0.00001 par value per share (NEUP) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 31 Oct 2025.
- Current filing was accepted on 06 Feb 2026, 16:29.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Baselake Partners, LP | 4.1% | 222,222 | 0 | 222,222 | /s/ David Paolella | David Paolella, Managing Member of Baselake Management, LLC, its investment manager | |
| Baselake Management, LLC | 4.1% | 222,222 | 0 | 222,222 | /s/ David Paolella | David Paolella, Managing Member | |
| David Paolella | 4.1% | 222,222 | 0 | 222,222 | /s/ David Paolella | Individually |